Cell Signaling Technology, Pfizer, Roche deal

Roche's Ventana Medical Systems Inc. tissue diagnostic unit, Pfizer and Cell Signaling Technology partnered to develop a fully-automated and standardized immunohistochemistry (IHC) companion diagnostic test to identify anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) patients. Ventana will develop the test, which will be based on Ventana's Ventana OptiView DAB detection and Cell Signaling's D5F3 antibody. The test will be used to assess whether Pfizer's Xalkori crizotinib may be an appropriate treatment. ...